论文部分内容阅读
目的分析2011-2016年河南省乙型肝炎疫苗(Hepatitis B Vaccine,HepB)疑似预防接种异常反应(Adverse Events Following Immunization,AEFI)的特征,评价HepB预防接种的安全性。方法通过中国免疫规划信息管理系统,收集2011-2016年河南省报告的HepB AEFI个案数据和HepB接种剂次数,采用描述流行病学方法进行分析。结果2011-2016河南省共报告HepB AEFI 2 522例,年平均报告发病率为68.77/100万剂。所有AEFI中,一般反应2 115例、异常反应82例、偶合症55例,分别占93.92%、3.64%、2.44%,年均报告发生率分别为64.58/100万剂、2.50/100万剂、1.68/100万剂。男女性别比为1.33∶1,AEFI主要集中在≤1岁、第3剂次和接种后≤1 d。报告月份主要集中在7-9月份,报告地区主要集中周口市、洛阳市和驻马店市等地。一般反应临床诊断均为发热、红肿、硬结,异常反应以过敏反应性疾病为主。所有AEFI,治愈或好转占98.53%,异常反应死亡1例,报告死亡发生率为0.33/100万剂。结论河南省HepB AEFI报告发生率较低,预后良好。
Objective To analyze the characteristics of Hepatitis B Vaccine (HepB) suspected antiviral immunization (AEFI) from 2011 to 2016 and evaluate the safety of HepB vaccination. Methods The HepB AEFI case data and HepB inoculant numbers reported in Henan Province from 2011 to 2016 were collected through the China Immunization Program Information Management System and analyzed by descriptive epidemiological method. Results A total of 2 522 cases of HepB AEFI were reported in Henan Province from 2011 to 2016, with an average annual incidence of 68.77 / 1 million doses. Among all the AEFIs, 2115 were normal reactions, 82 were abnormal reactions, and 55 were coupled diseases, accounting for 93.92%, 3.64% and 2.44% respectively. The annual average reported rates were 64.58 / 1 million doses and 2.50 / 1 million doses respectively, 1.68 / 1 million doses. The male-to-female sex ratio was 1.33: 1, with AEFI mainly concentrated in patients ≤1 years, in the third dose and after vaccination ≤1 d. The report month mainly concentrated in July-September. The report area mainly focused on Zhoukou City, Luoyang City and Zhumadian City. The general clinical response is fever, redness, induration, abnormal reaction to allergic diseases. Of all AEFIs, 98.53% were cured or improved, 1 died of abnormal reaction, and the reported death rate was 0.33 / 1 million doses. Conclusion The incidence of HepB AEFI in Henan Province is low and the prognosis is good.